{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:26:28Z","timestamp":1790767588986,"version":"4.1.0"},"reference-count":81,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY022372"],"award-info":[{"award-number":["EY022372"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The eye is at the forefront of developing therapies for genetic diseases. With the FDA approval of the first gene-therapy drug for a form of congenital blindness, numerous studies have been initiated to develop gene therapies for other forms of eye diseases. These examinations have revealed new information about the benefits as well as restrictions to using drug-delivery routes to the different parts of the eye. In this article, we will discuss a brief history of gene therapy and its importance to the eye and ocular delivery landscape that is currently being investigated, and provide insights into their advantages and disadvantages. Efficient delivery routes and vehicle are crucial for an effective, safe, and longer-lasting therapy.<\/jats:p>","DOI":"10.3390\/biom11081135","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T21:51:07Z","timestamp":1627854667000},"page":"1135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Ocular Gene Delivery Landscape"],"prefix":"10.3390","volume":"11","author":[{"given":"Bhubanananda","family":"Sahu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, UMass Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Chug","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, UMass Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, UMass Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1098\/rstb.2009.0099","article-title":"The evolution of early vertebrate photoreceptors","volume":"364","author":"Collin","year":"2009","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_2","unstructured":"Kandel, E.R. (2013). Principles of Neural Science, McGraw-Hill. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ng1092-93","article-title":"A brief history of gene therapy","volume":"2","author":"Friedmann","year":"1992","journal-title":"Nature Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.137.4.1091","article-title":"Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an argininemic patient","volume":"137","author":"Rogers","year":"1973","journal-title":"J. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: Initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1353\/hcr.2008.0022","article-title":"Eight years after Jesse\u2019s death, are human research subjects any safer?","volume":"38","author":"Gelsinger","year":"2008","journal-title":"Hastings Cent. Rep."},{"key":"ref_8","unstructured":"Daiger, S.P., Sullivan, L.S., and Bowne, S.J. (1996). The Retinal Information Network, The University of Texas Health Science Center at Houston."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrg2717","article-title":"Photoreceptor degeneration: Genetic and mechanistic dissection of a complex trait","volume":"11","author":"Wright","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103200","DOI":"10.1016\/j.ebiom.2020.103200","article-title":"Childhood-onset genetic cone-rod photoreceptor diseases and underlying pathobiology","volume":"63","author":"Garafalo","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-060909-153227","article-title":"The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders","volume":"33","author":"Bramall","year":"2010","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.gde.2012.04.006","article-title":"The ciliopathies: A transitional model into systems biology of human genetic disease","volume":"22","author":"Davis","year":"2012","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMra1010172","article-title":"Ciliopathies","volume":"364","author":"Hildebrandt","year":"2011","journal-title":"New Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17425247.2016.1227785","article-title":"Extended ocular drug delivery systems for the anterior and posterior segments: Biomaterial options and applications","volume":"14","author":"Dosmar","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4103\/1673-5374.306063","article-title":"The future of retinal gene therapy: Evolving from subretinal to intravitreal vector delivery","volume":"16","author":"Ross","year":"2021","journal-title":"Neural Regen. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/hum.2020.023","article-title":"Evaluation of Photoreceptor Transduction Efficacy of Capsid-Modified Adeno-Associated Viral Vectors Following Intravitreal and Subretinal Delivery in Sheep","volume":"31","author":"Ross","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_17","first-page":"1771","article-title":"Glycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2","volume":"17","author":"Allen","year":"2011","journal-title":"Mol. Vis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.oret.2018.01.016","article-title":"The genetics of retinopathy of prematurity: A model for neovascular retinal disease","volume":"2","author":"Swan","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1038\/mtm.2016.23","article-title":"Production and clinical development of nanoparticles for gene delivery","volume":"3","author":"Chen","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/sj.gt.3302761","article-title":"Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles","volume":"13","author":"Fink","year":"2006","journal-title":"Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12932","DOI":"10.1073\/pnas.94.24.12932","article-title":"Phagocytosis of rod outer segments by retinal pigment epithelial cells requires alpha(v)beta5 integrin for binding but not for internalization","volume":"94","author":"Finnemann","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0014-4835(91)90130-7","article-title":"Mannose-sensitive HRP endocytosis by the retinal pigment epithelium","volume":"52","author":"Heth","year":"1991","journal-title":"Exp. Eye Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/nar\/25.15.3095","article-title":"Nanoscopic structure of DNA condensed for gene delivery","volume":"25","author":"Dunlap","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Farjo, R., Skaggs, J., Quiambao, A.B., Cooper, M.J., and Naash, M.I. (2006). Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE, 1.","DOI":"10.1371\/journal.pone.0000038"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1083\/jcb.100.5.1676","article-title":"Endocytosis and degradation of interstitial retinol-binding protein: Differential capabilities of cells that border the interphotoreceptor matrix","volume":"100","author":"Hollyfield","year":"1985","journal-title":"J. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.33.1.61","article-title":"The renewal of photoreceptor cell outer segments","volume":"33","author":"Young","year":"1967","journal-title":"J. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: Journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymeth.2003.11.023","article-title":"Advanced transfection with Lipofectamine 2000 reagent: Primary neurons, siRNA, and high-throughput applications","volume":"33","author":"Dalby","year":"2004","journal-title":"Methods"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40824-019-0156-z","article-title":"Recent advances in the development of gene delivery systems","volume":"23","author":"Sung","year":"2019","journal-title":"Biomater. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"326497","DOI":"10.1155\/2011\/326497","article-title":"Liposomes for use in gene delivery","volume":"2011","author":"Balazs","year":"2011","journal-title":"J. Drug Deliv."},{"key":"ref_34","first-page":"1914","article-title":"Gene transfer with liposomes to the intraocular tissues by different routes of administration","volume":"37","author":"Masuda","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jfb6020379","article-title":"Lipid Nanoparticles for Ocular Gene Delivery","volume":"6","author":"Wang","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.omtn.2017.02.005","article-title":"Targeted Multifunctional Lipid ECO Plasmid DNA Nanoparticles as Efficient Non-viral Gene Therapy for Leber\u2019s Congenital Amaurosis","volume":"7","author":"Sun","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jconrel.2015.10.007","article-title":"Non-viral therapeutic approaches to ocular diseases: An overview and future directions","volume":"219","author":"Zulliger","year":"2015","journal-title":"J. Control Release"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Rai, R., Alwani, S., and Badea, I. (2019). Polymeric Nanoparticles in Gene Therapy: New Avenues of Design and Optimization for Delivery Applications. Polymers, 11.","DOI":"10.3390\/polym11040745"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1172\/JCI64833","article-title":"DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice","volume":"122","author":"Han","year":"2012","journal-title":"J. Clin. Invest."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jconrel.2013.08.299","article-title":"Persistence of non-viral vector mediated RPE65 expression: Case for viability as a gene transfer therapy for RPE-based diseases","volume":"172","author":"Koirala","year":"2013","journal-title":"J. Control Release"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/hmg\/ddt013","article-title":"S\/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA","volume":"22","author":"Koirala","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41587-019-0402-x","article-title":"Emerging patent landscape for non-viral vectors used for gene therapy","volume":"38","author":"Pereira","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jconrel.2018.07.013","article-title":"Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product","volume":"285","author":"Touchard","year":"2018","journal-title":"J. Control Release"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/gt.2008.113","article-title":"Persistent episomal transgene expression in liver following delivery of a scaffold\/matrix attachment region containing non-viral vector","volume":"15","author":"Argyros","year":"2008","journal-title":"Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1096\/fj.15-270363","article-title":"Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype","volume":"29","author":"Han","year":"2015","journal-title":"FASEB J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/978-1-4614-3209-8_90","article-title":"Gene therapy for Stargardt disease associated with ABCA4 gene","volume":"801","author":"Han","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-12-386509-0.00003-X","article-title":"Retrovirus and lentivirus vector design and methods of cell conditioning","volume":"507","author":"Cooray","year":"2012","journal-title":"Methods Enzymol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_49","first-page":"700","article-title":"Viral Vectors for Gene Therapy: Current State and Clinical Perspectives","volume":"81","author":"Lukashev","year":"2016","journal-title":"Biochemistry"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1172\/JCI120429","article-title":"Gene therapy and genome surgery in the retina","volume":"128","author":"DiCarlo","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1167\/iovs.13-11871","article-title":"Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: Safety and biodistribution of StarGen for Stargardt disease","volume":"54","author":"Binley","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"ref_52","first-page":"3819","article-title":"Early findings in a phase I\/IIa clinical program for stargardt disease (STGD1, MIM # 248200)","volume":"56","author":"Audo","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2155179018822781","DOI":"10.1177\/2155179018822781","article-title":"Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?","volume":"11","author":"Seimetz","year":"2019","journal-title":"Cell Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14712598.2015.993374","article-title":"Adenoviruses as gene\/vaccine delivery vectors: Promises and pitfalls","volume":"15","author":"Appaiahgari","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","article-title":"Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency","volume":"96","author":"Wilson","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: An update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"ref_58","first-page":"137","article-title":"Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo","volume":"3","author":"Yang","year":"1996","journal-title":"Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/jvi.9.2.394-396.1972","article-title":"Separation of two types of adeno-associated virus particles containing complementary polynucleotide chains","volume":"9","author":"Berns","year":"1972","journal-title":"J. Virol"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated Defective Virus Particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/gt.2008.170","article-title":"Tailoring the AAV vector capsid for gene therapy","volume":"16","author":"Vandenberghe","year":"2009","journal-title":"Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Buck, T.M., and Wijnholds, J. (2020). Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124197"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ng0501-92","article-title":"Gene therapy restores vision in a canine model of childhood blindness","volume":"28","author":"Acland","year":"2001","journal-title":"Nature Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1073\/pnas.1118847109","article-title":"Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa","volume":"109","author":"Beltran","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ymthe.2017.05.005","article-title":"Codon-Optimized RPGR Improves Stability and Efficacy of AAV8 Gene Therapy in Two Mouse Models of X-Linked Retinitis Pigmentosa","volume":"25","author":"Fischer","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40259-020-00453-8","article-title":"Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration","volume":"34","author":"Basiri","year":"2020","journal-title":"BioDrugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.gt.3303074","article-title":"Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2\/8","volume":"15","author":"Natkunarajah","year":"2008","journal-title":"Gene Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/gt.2017.85","article-title":"Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina","volume":"24","author":"Hickey","year":"2017","journal-title":"Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/mt.2008.269","article-title":"High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors","volume":"17","author":"Dinculescu","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/hum.2020.070","article-title":"Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea","volume":"31","author":"Frederick","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-030-27378-1_18","article-title":"Systemic Delivery of Genes to Retina Using Adeno-Associated Viruses","volume":"1185","author":"Simpson","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Chan, Y.K., Wang, S.K., Chu, C.J., Copland, D.A., Letizia, A.J., Costa Verdera, H., Chiang, J.J., Sethi, M., Wang, M.K., and Neidermyer, W.J. (2021). Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci. Transl. Med., 13.","DOI":"10.1126\/scitranslmed.abd3438"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/eye.2009.270","article-title":"Long-term follow-up of a family with dominant X-linked retinitis pigmentosa","volume":"24","author":"Wu","year":"2010","journal-title":"Eye"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1089\/hum.2004.15.896","article-title":"Trans-splicing adeno-associated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency","volume":"15","author":"Xu","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Trapani, I. (2019). Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina. Genes, 10.","DOI":"10.3390\/genes10040287"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/hum.2010.122","article-title":"Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences","volume":"22","author":"Ghosh","year":"2011","journal-title":"Hum. Gene Ther."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/8\/1135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:38:48Z","timestamp":1760164728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/8\/1135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["biom11081135"],"URL":"https:\/\/doi.org\/10.3390\/biom11081135","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}